Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.50 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.38 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 3/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | IDH2 | P48735 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | TTK | P33981 | 1/20 | 0.30 |
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659819 | 1.00 | MPO (0.50) | MPOBMPR1AACVRL1ACVR1ACHE | |
| SCHEMBL659820 | 1.00 | MPO (0.50) | MPOBMPR1AACVRL1ACVR1ACHE | |
| SCHEMBL22013247 | 0.83 | MPO (0.49) | MPOACHEIDH1IDH2JAK1 | |
| SCHEMBL670597 | 0.82 | — | — | |
| SCHEMBL23013386 | 0.81 | ESR2 (0.42) | MPOBMPR1AACVRL1ACVR1ACHE | |
| SCHEMBL27322625 | 0.81 | OGA (0.43) | BMPR1AACVRL1ACVR1ACHEESR2 | |
| SCHEMBL23022243 | 0.81 | ESR2 (0.42) | MPOBMPR1AACVRL1ACVR1ACHE | |
| SCHEMBL15416353 | 0.80 | MPO (0.50) | MPOACHECHRNB2CHRNA4 | |
| SCHEMBL15431350 | 0.80 | MPO (0.50) | MPOACHECHRNB2CHRNA4 | |
| SCHEMBL14863089 | 0.78 | MPO (0.59) | MPOBMPR1AACVRL1ACVR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289712-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2022-09-15 | — | — | US | disclosed |
| CN-114341127-A | Aminopyrazine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021032148-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-02-25 | — | — | WO | disclosed |
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2534156-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| WO-2011100502-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | MPO 3843/4885BMPR1A 1993/4885ACVRL1 2387/4885 |
| US-20220289712-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | MAPKAPK5, STK25, STK35 | MPO 2476/4885BMPR1A 3552/4885ACVRL1 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.